On June 13, 2018, Senator Orrin Hatch (R-UT) introduced to the Senate Judiciary Committee an amendment to restore the careful balance sought in the Hatch-Waxman Act, which provided incentives for both pharmaceutical innovation and drug affordability. The amendment, titled the Hatch-Waxman Integrity Act of 2018, would modify the IPR process for pharmaceuticals—under Hatch-Waxman and the BPCIA—and would amend sections of the Federal Food, Drug and Cosmetic Act that provide abbreviated pathways for generic drug and biosimilar product approval.
Continue Reading Proposed Hatch-Waxman Amendment Would Effectively Eliminate IPR Challenges by Generics
Chelsea M. Murray
Chelsea M. Murray recently joined the firm as an Associate in 2019. Ms. Murray was a Summer Associate in the IP Litigation practice group, supporting our Electrical & Computer Technology and Litigation clients. Ms. Murray is proficient in the programming languages of Java, C++, Ruby on Rails, Erlang, HTML, CSS, and Scratch.